Jennifer Good
Principal executive officer pay for Jennifer Good, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Trevi Therapeutics, Inc. (TRVI) FY2023–FY2025
Aligned: paid up as stock roseCAP $1,107,263→$15,377,546 while $100 invested went $69.43→$648.70
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $1.7M | $1.1M |
| FY2024 | $2.6M | $5.0M |
| FY2025 | $3.9M | $15.4M |
The company's "$100 invested" index ran $69.43 at FY2023 → $648.70 by FY2025 — an annualized return of 205.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 205.7%/yr at TRVI ( FY2023–FY2025). See the CEO track-record ranking for context.